Subcutaneous CSF Atomizer for Shunt Reliability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating hydrocephalus, such as ventriculoperitoneal shunting, have high failure rates and associated risks like infection, occlusion, and discomfort due to the need for tunneling catheters under the skin, and do not effectively address the imbalance between CSF production and absorption.
Innovation Solution
A method and device that involves drawing excess CSF from the ventricles and converting it into a low-velocity aerosol of ultrafine droplets using a subcutaneous atomizer, which evaporates in the subcutaneous space, allowing for absorption into the bloodstream or diffusion through the skin, thereby reducing the need for invasive catheter placement and minimizing risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ventriculoperitoneal shunting is used to divert CSF, then CSF removal is achieved, but the risk of infection, occlusion, disconnection, and other complications increases
Solution Approach 1:
The patent extracts the harmful intermediate step of long subcutaneous tunneling and peritoneal cavity access. Instead of routing CSF through a long external tunnel to the peritoneum, the invention removes the excess CSF directly at the ventricle site and evaporates it locally in the subcutaneous space near the ventricle, eliminating the long catheter tunnel that is prone to infection and occlusion.
Solution Approach 2:
The patent introduces an intermediary substance - a hydrophobic coating on the catheter surface - that prevents CSF from adhering to the catheter wall. This intermediary layer eliminates the problem of CSF stagnation and bacterial biofilm formation on the catheter surface, significantly reducing occlusion and infection risks while maintaining CSF flow.
2Reliability
If a long catheter is tunneled under the skin to reach the peritoneum, then CSF diversion is achieved, but the risk of disconnection, migration, and discomfort increases
Solution Approach 1:
The patent removes the long subcutaneous tunnel component from the shunt system. By evaporating CSF locally at the ventricle site rather than transporting it to the peritoneum, the invention eliminates the long catheter tunnel that causes disconnection, migration, and patient discomfort.
Solution Approach 2:
Instead of the traditional approach of transporting CSF away from the brain to another body cavity, the patent inverts the approach by removing and evaporating CSF right at the ventricle site. This reversal eliminates the need for long catheter tunnels and associated complications.
3Productivity
If traditional shunting methods are used, then CSF removal is achieved, but the failure rate remains high requiring frequent revisions
Solution Approach 1:
The patent replaces the mechanical gravity-dependent flow system with a controlled evaporation system. Instead of relying on gravity and pressure gradients to move CSF through long tunnels, the invention uses localized heating to evaporate CSF directly at the ventricle site, providing more reliable and controllable CSF removal without the mechanical failures of traditional shunts.
Solution Approach 2:
The hydrophobic coating acts as an intermediary that ensures smooth CSF flow through the catheter by preventing adhesion and biofilm formation. This intermediary layer maintains catheter patency and prevents occlusion, significantly improving shunt durability and reducing revision rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially reduces the risk of complications and shunt revisions by effectively managing excess CSF through evaporation and diffusion, providing a safer and more reliable method for fluid removal.
Implementation Method 1
converting the CSF from the bulk liquid form into another form that is readily evaporated or diffused through the subject's skin
Implementation Method 2
the ultrafine CSF droplets evaporate at a body temperature of 37° C. Remaining CSF vapors are disposed by absorption into a capillary bed and bloodstream of the subject and/or by diffusion through subject's scalp and skin
Implementation Method 3
Remaining CSF vapors are disposed by absorption into a capillary bed and bloodstream of the subject
Implementation Method 4
Remaining CSF vapors are disposed by absorption into a capillary bed and bloodstream of the subject and/or by diffusion through subject's scalp and skin as perspiration
Data Source
AI summary
A method for removing bodily fluid includes drawing bodily fluid that has accumulated in excess, converting the drawn fluid from bulk liquid form to aerosol form, and disposing of the aerosol via evaporation of liquid droplets and absorption and/or diffusion of vapor. Conversion from bulk liquid to aerosol may include collecting the bulk liquid fluid in a reservoir, conveying the bulk liquid bodily fluid to an atomizer, converting the bulk liquid fluid into an aerosol having ultrafine droplets, and ejecting the aerosol into a subcutaneous space for disposal via evaporation of liquid droplets and absorption and/or diffusion of vapors. The method may be performed with a subcutaneous atomizer that may be controlled locally or by an external transmitter for effecting a conversion and mist rate to keep pace with the accumulation of excess bodily fluid.